Mainz Biomed N.V. (MYNZ) Stock Price, Quote & News

Company Profile

Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes its IVD kits to third-party laboratories. The company has a collaboration agreement with Thermo Fishe...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 49 6131 554 2860

Website: mainzbiomed.com

Address:

Robert Koch Strasse 50, Mainz, Germany

Duskfall Sep. 11 at 2:57 PM

$GLMD $GLMD Here's a bit of DD 📋🖋️ 1. AM-001 Study Aramchol Meglumine Suspension 400 mg achieved approximately double the AUC (exposure) compared to the older Aramchol acid tablet version. This AM-001 study is expected to be completed in the 🚨second half of 2025! 2. Oncological studies A Phase 1b study for the Regorafenib + Aramchol combination is planned for 🚨Q4 2025. More DD coming at some point.. It's rare that I post these. Usually I don't😴 I also like these setups👇 $TNFA $MYNZ $INTS $VYNE

0 · Reply

Orlandotrader Sep. 11 at 11:48 AM

$MYNZ Patiently awaiting Preliminary Results of CholoAlert Efficacy!!! I’m sure it won’t Disappoint.

1 · Reply

bestonlinetrades_com Sep. 10 at 7:04 PM

$MYNZ ColoAlert is designed for profitability, rapid commecial update, and broad consumer acceptance.

0 · Reply

bestonlinetrades_com Sep. 10 at 7:01 PM

$MYNZ $XBI $IBB Mainz biomed on its way to $50 to $100

0 · Reply

bestonlinetrades_com Sep. 10 at 6:53 PM

$MYNZ $IBB $XBI Mainz looking very explosive !!! Monthly RSI about to cross NORTH

1 · Reply

bestonlinetrades_com Sep. 10 at 6:46 PM

$MYNZ $IBB $XBI Mainz biomed looking very explosive down there. End of year seasonality favoring small caps and biotech, forward looking news on trial, and launching into new year FDA Approval in USA opening multi billion dollar markets....

0 · Reply

wtrade09 Sep. 10 at 4:52 PM

$MYNZ

0 · Reply

bestonlinetrades_com Sep. 10 at 11:27 AM

$MYNZ $XBI $IBB meanwhile major biotech indices are making major new bull market breakouts north from 4 year downtrends .

0 · Reply

ridgecrest123 Sep. 9 at 2:21 PM

$MYNZ pretty good buy of 11k this morning. Hopefully bullish sign!

0 · Reply

MoneyFox562 Sep. 9 at 1:54 PM

$MYNZ

0 · Reply

Mainz Biomed Announces Registration of ColoAlert in the United Kingdom

Aug 13, 2025, 8:01 AM EDT - 4 weeks ago

Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert®

Aug 4, 2025, 10:22 AM EDT - 5 weeks ago

Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants

Jul 23, 2025, 8:01 AM EDT - 7 weeks ago

Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance Companies

Jul 15, 2025, 8:01 AM EDT - 2 months ago

Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition

Jun 25, 2025, 8:01 AM EDT - 2 months ago

Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test

Jun 10, 2025, 9:01 AM EDT - 3 months ago

Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project

May 19, 2025, 8:01 PM EDT - 4 months ago

Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants

May 16, 2025, 8:01 AM EDT - 4 months ago

Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study

Apr 29, 2025, 8:01 AM EDT - 4 months ago

Mainz Biomed Enters into Technology Partnership with EDX Medical Group

Apr 28, 2025, 8:01 AM EDT - 4 months ago

Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval

Mar 27, 2025, 9:01 AM EDT - 6 months ago

Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study

Mar 13, 2025, 8:01 AM EDT - 6 months ago

Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer

Mar 3, 2025, 8:01 AM EST - 6 months ago

Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention

Feb 20, 2025, 8:01 AM EST - 7 months ago

Mainz Biomed Expands into Switzerland with labor team w

Feb 11, 2025, 8:01 AM EST - 7 months ago

Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month

Jan 27, 2025, 8:01 AM EST - 8 months ago

Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements

Jan 21, 2025, 8:01 AM EST - 8 months ago

Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population

Dec 19, 2024, 8:01 AM EST - 9 months ago

Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test

Dec 16, 2024, 5:00 PM EST - 9 months ago

Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering

Dec 12, 2024, 8:00 PM EST - 9 months ago

Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules

Dec 3, 2024, 2:40 PM EST - 10 months ago

Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific

TMO

Nov 29, 2024, 8:45 AM EST - 10 months ago

Mainz Biomed Announces Stock Split

Oct 21, 2024, 8:01 AM EDT - 11 months ago

Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update

Oct 8, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version

Oct 1, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025

Sep 18, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador

Sep 4, 2024, 4:01 AM EDT - 1 year ago

Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert

Jul 25, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience

Jul 9, 2024, 3:01 AM EDT - 1 year ago

Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test

Jul 2, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Provides Half Year 2024 Corporate Update

Jun 3, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024

May 31, 2024, 5:01 PM EDT - 1 year ago

Mainz Biomed Reports Results of 2024 Annual General Meeting

May 28, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting

May 20, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial

May 7, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.

Apr 25, 2024, 9:29 AM EDT - 1 year ago

Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic

Apr 9, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Reports Full Year 2023 Financial Results

Mar 19, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment

Mar 18, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options

Mar 12, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations

Mar 5, 2024, 8:01 AM EST - 1 year ago

Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic

Feb 27, 2024, 8:01 AM EST - 1 year ago

Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community

Feb 22, 2024, 8:01 AM EST - 1 year ago

Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®

Feb 21, 2024, 8:01 AM EST - 1 year ago

Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy

Feb 6, 2024, 8:01 AM EST - 1 year ago

Mainz Biomed Establishes Physician-Led Laboratory Expanding Service Offering for Privately Insured Patients in Germany

Jan 11, 2024, 8:01 AM EST - 1 year ago

Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium

Jan 9, 2024, 8:01 AM EST - 1 year ago

Mainz Biomed Provides Year-End Corporate Review 2023

Dec 19, 2023, 3:39 PM EST - 1 year ago

Is This BioTech Play Severely Undervalued? BioTech Shares Promising Results From Colorectal Study

Dec 19, 2023, 8:01 AM EST - 1 year ago

Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees

Duskfall Sep. 11 at 2:57 PM

0 · Reply

Orlandotrader Sep. 11 at 11:48 AM

$MYNZ Patiently awaiting Preliminary Results of CholoAlert Efficacy!!! I’m sure it won’t Disappoint.

1 · Reply

bestonlinetrades_com Sep. 10 at 7:04 PM

$MYNZ ColoAlert is designed for profitability, rapid commecial update, and broad consumer acceptance.

0 · Reply

bestonlinetrades_com Sep. 10 at 7:01 PM

$MYNZ $XBI $IBB Mainz biomed on its way to $50 to $100

0 · Reply

bestonlinetrades_com Sep. 10 at 6:53 PM

$MYNZ $IBB $XBI Mainz looking very explosive !!! Monthly RSI about to cross NORTH

1 · Reply

bestonlinetrades_com Sep. 10 at 6:46 PM

0 · Reply

wtrade09 Sep. 10 at 4:52 PM

$MYNZ

0 · Reply

bestonlinetrades_com Sep. 10 at 11:27 AM

$MYNZ $XBI $IBB meanwhile major biotech indices are making major new bull market breakouts north from 4 year downtrends .

0 · Reply

ridgecrest123 Sep. 9 at 2:21 PM

$MYNZ pretty good buy of 11k this morning. Hopefully bullish sign!

0 · Reply

MoneyFox562 Sep. 9 at 1:54 PM

$MYNZ

0 · Reply

wtrade09 Sep. 9 at 12:26 PM

$MYNZ 4 hr

0 · Reply

Tbio64 Sep. 9 at 11:52 AM

$MYNZ waiting for big news...maybe today at 2.14 pm

2 · Reply

MoneyFox562 Sep. 9 at 4:35 AM

$MYNZ We get great news! We keep waiting But…

0 · Reply

tr53 Sep. 8 at 3:50 PM

$MYNZ Oh man - this stock really seems to interest nobody anymore. But no wonder - I'm invested!

0 · Reply

feynman52 Sep. 8 at 2:47 PM

$MYNZ

0 · Reply

ridgecrest123 Sep. 4 at 12:30 PM

$MYNZ any ideas when ER will be released?

1 · Reply

Michaellll Sep. 2 at 5:42 PM

$MYNZ price doesn’t make sense holding my shares

1 · Reply

tr53 Sep. 2 at 4:21 PM

$MYNZ No one has the stock on their radar.

1 · Reply

bestonlinetrades_com Sep. 2 at 1:33 PM

$MYNZ $IBB $XBI nice to see the biotech indices skyrocketing today along with MYNZ

0 · Reply

tr53 Sep. 2 at 1:05 PM

$MYNZ Not bad - this could shoot up now.

0 · Reply

Tbio64 Sep. 2 at 12:16 PM

$MYNZ

0 · Reply

HorsePicks Sep. 2 at 12:13 PM

$MYNZ $MYNZ: Mainz Biomed's ColoAlert Receives MHRA Approval For Colorectal Cancer Screening In The UK

0 · Reply

Market Cap	7.60M
Revenue (ttm)	890,000.00
Net Income (ttm)	-21.65M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,432.58%
Debt to Equity Ratio	0.18

Volume	42,800
Avg Vol	153,212
Day's Range	N/A - N/A
Shares Out	4.58M
Stochastic %K	38%
Beta	0.25
Analysts	Strong Sell
Price Target	$14.00